Alembic Pharmaceuticals gains 2% on USFDA approval for Dapagliflozin tablets

The company now have a total of 99 ANDA approvals (88 final approvals and 11 tentative approvals) from USFDA.

Shares of Alembic Pharmaceuticals gained 2 percent intraday July 23 after the company received approval from the US Food & Drug Administration (USFDA).


The company has received tentative approval from the USFDA for its abbreviated new drug application (ANDA) Dapagliflozin tablets, 5 mg, and 10 mg, as per company release on BSE.

Dapagliflozin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The company now have a total of 99 ANDA approvals (88 final approvals and 11 tentative approvals) from USFDA.

At 10:48 hrs Alembic Pharmaceuticals was quoting at Rs 523, up to Rs 10.90, or 2.13 percent on the BSE.

Get a 2 days free trial in Stock Market Tips and MCX Tips  

Comments

Popular posts from this blog

Technical Classroom: How to use Fibonacci Retracement Levels in stock trading

Veto Switchgears jumps 5% on realisation of unsecured loan

Trade Setup for Wednesday: Top 15 things to know before Opening Bell